LLY
StockEli Lilly and Co
- HQ
- US
- Sector
- Pharmaceuticals
- Issued
- 1985-01-13
- Shares out.
- 942M
Performance
1 h agoKey statistics
1 h ago- Market cap
- $1.01T
- Enterprise value
- $1.04T
- P/E (TTM)
- 39.81
- Forward P/E
- 27.51
- P/E (annual)
- 48.75
- PEG
- 1.37
- P/B
- 38.29
- P/S (TTM)
- 13.93
- P/S (annual)
- 15.44
- EV / EBITDA
- 31.11×
- EV / Revenue
- 14.45×
- EPS (TTM)
- $28.15
- EPS (annual)
- $22.95
- Basic EPS (TTM)
- $28.15
- Book value / share
- $28.09
- Gross margin
- 82.83%
- Operating margin
- 43.63%
- Net margin
- 34.99%
- Return on equity (ROE)
- 101.31%
- Return on assets (ROA)
- 22.73%
- Return on investment (ROI)
- 37.71%
- EBITDA / share
- $37.37
- Revenue / share (TTM)
- $80.64
- Revenue growth (TTM YoY)
- +47.44%
- Revenue growth (Q YoY)
- +55.55%
- EPS growth (TTM YoY)
- +128.83%
- Dividend yield (indicated)
- 0.64%
- Dividend yield (TTM)
- 0.56%
- Dividend / share (TTM)
- $5.91
- Payout ratio
- 22.10%
- Current ratio
- 1.58
- Quick ratio
- 0.78
- Debt / equity
- 1.60
- LT debt / equity
- 1.54
- Beta
- 0.52
- Volatility (3M)
- 37.57%
Analyst ratings
1 h agoEarnings
1 h agoRelated news
1 h ago- Yahoo·5 d agocompanyCVS obesity drug deal puts Lilly on equal footing with Novo
The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.
- Yahoo·5 d agocompanyFoundayo and Zepbound now covered for millions of Americans
Eli Lilly and Company (NYSE: LLY) today announced an access milestone in obesity care: all three of the nation's largest pharmacy benefit managers (PBMs) will cover Lilly's full obesity medicine portfolio. This significantly expands the number of Americans who can access FDA-approved options through their existing insurance.
- Yahoo·5 d agocompanyIs Johnson & Johnson Stock Outperforming the Dow?
Johnson & Johnson has outperformed the Dow Jones over the past year, and analysts remain moderately optimistic about the stock’s outlook.
- SeekingAlpha·5 d agocompanyEli Lilly Expands Into Infectious Diseases, Retatrutide Adds Another Phase 3 Win
Eli Lilly continues strong execution, exceeding revenue expectations and expanding its pipeline with strategic, low-risk acquisitions in infectious diseases...
- SeekingAlpha·5 d agocompanyWall Street Underestimates Novo Nordisk's GLP-1 Comeback
Novo Nordisk A/S is closing in on Eli Lilly in the GLP-1 market despite Ozempic declines. Click for this NVO stock update.
- Yahoo·5 d agocompanyLLY, NVO Stocks Led May’s GLP-1 Rally — But This Smaller ‘Differentiated Player’ Got A Bold 160% Upside Call
Truist called Viking a “differentiated player” in the crowded obesity market, highlighting its flagship VK2735 candidate and dual oral-plus-injectable GLP-1 strategy.
- CNBC·6 d agocompanyCVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans
CVS will add Zepbound coverage on Oct. 1, and start covering Lilly's newly approved Foundayo pill on June 1.
- SeekingAlpha·6 d agocompanyEli Lilly: Big Upside Likely (Rating Upgrade)
Eli Lilly's robust guidance despite higher costs on acquisitions and underwhelming performance by Foundayo indicates its strength. See why LLY stock is a Strong Buy.
